조절되지 않는 제 1형 청소년 당뇨병 환자에서Insulin Glargine 치료의 효과
Effect of Insulin Glargine in Adolescents with Uncontrolled type 1 Diabetes Mellitus
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose : With long acting time of 24 hours and no peak concentration, insulin glargine (Lantus®, Aventis Pharma, Frankfurt, Germany) is preferably used as basal insulin to control fasting glucose level. The study was undertaken to evaluate the effect of insulin glargine as a basal insulin of intensive insulin therapy in uncontrolled type 1 diabetic adolescent patients. Methods : The subject included 47 uncontrolled type 1 diabetic patients who have been treated by NPH and RI or insulin lispro. They were followed up for the mean duration of 7.2 months. Clinical parameters including treatment duration, fasting plasma glucose, glycosylated hemoglobin, total insulin doses, body weight, and body mass index were analyzed and compared before and after introduction of insulin glargine therapy. Mean age was 16.0±2.8 years old. Results : Glycosylated hemoglobin was significantly decreased (9.4±1.4% to 8.6±1.4%, P<0.001) and fasting blood glucose level was also significantly decreased (182.6±53.2 mg/dL to 129.1±52.3 mg/dL, P<0.001, n=18) after switching to insulin glargine. Body weight increased significantly (56.4±9.4 kg to 57.9±9.6 kg, P=0.022) but increment of both total insulin dose (1.03±0.32 unit/kg/day to 1.04±0.29 unit/kg/day) and body mass index were insignificant. The mean dose of insulin glargine was 0.42±0.13 unit/kg/day. Conclusion : Insulin glargine as a basal insulin of intensive insulin therapy is more efficacious in diabetic control in adolescents with uncontrolled type 1 diabetes mellitus than conventional insulin therapy. Long-term follow up is needed for evaluating the effect of insulin glargine on diabetic control, prevention of hypoglycemia, and complication.
Abstract
Purpose : With long acting time of 24 hours and no peak concentration, insulin glargine (Lantus®, Aventis Pharma, Frankfurt, Germany) is preferably used as basal insulin to control fasting glucose level. The study was undertaken to evaluate the effect of insulin glargine as a basal insulin of intensive insulin therapy in uncontrolled type 1 diabetic adolescent patients. Methods : The subject included 47 uncontrolled type 1 diabetic patients who have been treated by NPH and RI or insulin lispro. They were followed up for the mean duration of 7.2 months. Clinical parameters including treatment duration, fasting plasma glucose, glycosylated hemoglobin, total insulin doses, body weight, and body mass index were analyzed and compared before and after introduction of insulin glargine therapy. Mean age was 16.0±2.8 years old. Results : Glycosylated hemoglobin was significantly decreased (9.4±1.4% to 8.6±1.4%, P<0.001) and fasting blood glucose level was also significantly decreased (182.6±53.2 mg/dL to 129.1±52.3 mg/dL, P<0.001, n=18) after switching to insulin glargine. Body weight increased significantly (56.4±9.4 kg to 57.9±9.6 kg, P=0.022) but increment of both total insulin dose (1.03±0.32 unit/kg/day to 1.04±0.29 unit/kg/day) and body mass index were insignificant. The mean dose of insulin glargine was 0.42±0.13 unit/kg/day. Conclusion : Insulin glargine as a basal insulin of intensive insulin therapy is more efficacious in diabetic control in adolescents with uncontrolled type 1 diabetes mellitus than conventional insulin therapy. Long-term follow up is needed for evaluating the effect of insulin glargine on diabetic control, prevention of hypoglycemia, and complication.
참고문헌 (18)
- Deiss D., "Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes", Pediatr Diabetes, 8, pp.157~162 (2007)
- The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus", N Engl J Med, 329, pp.977~986 (1993)
- Owens D.R., "Insulins today and beyond", Lancet, 358, pp.739~746 (2001)
- Porcellati F., "Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin", Diabet Med, 21, pp.1213~1220 (2004)
- Gale E.A., "A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy.", Diabet Med, 17, pp.209~214 (2000)
- Del Sindaco P., "Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection- meal", Diabet Med, 15, pp.592~600 (1998)
- Siebenhofer A., "Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus", Cochrane Database Syst Rev, CD003287 (2006)
- Hathout E.H., "Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes", Diabetes Technol Ther, 5, pp.801~806 (2003)
- Kanazawa Y., "Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2)", Endocr J, 54, pp.975~983 (2007)
- Wang F., "Insulin glargine: a systematic review of a long-acting insulin analogue", Clin Ther, 25, pp.1541~1577 (2003)
- Chatterjee S., "Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes-the glargine and aspart study (GLASS) a randomised cross-over study", Diabetes Res Clin Pract, 77, pp.215~222 (2007)
- Rhie Y.J., "The effect of Lantus on glycemic control in children and adolescents with type 1 diabetes mellitus", Korean J Pediatr, 50, pp.565~569 (2007)
- Raskin P., "16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes", Diabetes Care, 23, pp.1666~1671 (2000)
- de Boer H., "Ruineman-Koerts J. Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen", Diabetes Obes Metab, 8, pp.517~523 (2006)
- 질병관리본부 만성병조사팀, "소아.청소년 표준 성장도표", 소아.청소년 신체발육표준치 제정위원회대한소아과학회 (2007), 서울
- Ogden C.L., "Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version", Pediatrics, 109, pp.45~60 (2002)
- Giannini C., "Role of physical exercise in children and adolescents with diabetes mellitus", J Pediatr Endocrinol Metab, 20, pp.173~184 (2007)
- Riddell M.C., "Physical activity, sport, and pediatric diabetes", Pediatr Diabetes, 7, pp.60~70 (2006)